AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23937405 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III (XE), active application (XEA)
Number of subjects: 31
Study 23937405 — intervention group
Group type: COMPARATOR
Intervention: Xeno III (XE), passive application (XEP)
Number of subjects: 31
Study 22935960 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 1,200 mg
Number of subjects: 14
Study 22935960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18952228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (450 mg/d in 3 doses for 6 days)
Number of subjects: 20
Study 18952228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose, identical administration)
Number of subjects: 20
Study 17615450 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program for safe drug use (1.5 hours, once a week for 3 weeks)
Number of subjects: 40
Study 17615450 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education program)
Number of subjects: 40
Study 15097245 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 20 mg
Number of subjects: 1039
Study 15097245 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg
Number of subjects: 1039
Study 15097245 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 1039
Study 15097245 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 1039
Study 15097245 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1039
Study 11579944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg twice weekly for 12 weeks)
Number of subjects: 17
Study 11579944 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (2.5 mg or 5 mg twice daily for 12 weeks)
Number of subjects: 17
Study 9538967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro
Number of subjects: 23
Study 7854921 — intervention group
Group type: COMPARATOR
Intervention: Discriminant analysis using parameters from 99mTc‐MAG3 renogram (mean transit time, time at 20% of initial height, time to peak).
Number of subjects: 82
Study 3122919 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy conducted by general practitioners in group sessions once a week for eight weeks, accompanied by galvanic skin resistance biofeedback.
Number of subjects: 0
Study 3122919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relaxation therapy).
Number of subjects: 0
Study 3122919 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy conducted by general practitioners.
Number of subjects: 0
Study 30516328 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid induction chemotherapy (COJEC)
Number of subjects: 69
Study 30516328 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-weekly chemotherapy
Number of subjects: 69
Study 28351880 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based play intervention
Number of subjects: 1752
Study 26154816 — intervention group
Group type: EXPERIMENTAL
Intervention: B-Complex (n=21)
Number of subjects: 56
Study 26154816 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum mineral/vitamin formula (BSMV, n=18)
Number of subjects: 56
Study 26154816 — intervention group
Group type: COMPARATOR
Intervention: Single nutrient (vitamin D, n=17)
Number of subjects: 56
Study 23632233 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 30.0-34.9
Number of subjects: 86000
Study 23632233 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 35.0-39.9
Number of subjects: 86000
Study 23632233 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 40.0+
Number of subjects: 86000
Study 23632233 — intervention group
Group type: COMPARATOR
Intervention: Normal BMI (18.5-24.9)
Number of subjects: 86000
Study 17148625 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 300
Study 17148625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 14669815 — intervention group
Group type: EXPERIMENTAL
Intervention: Master Amino Acid Pattern (MAP®) as a dietary protein substitute
Number of subjects: 0
Study 10437621 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic repair (TAPP and TEP)
Number of subjects: 41
Study 10437621 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture technique and tension-free surgery
Number of subjects: 41
Study 8553384 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-based transcranial color-coded duplex sonography (p-TCCD)
Number of subjects: 30
Study 8553384 — intervention group
Group type: COMPARATOR
Intervention: Frequency-based transcranial color-coded duplex sonography (f-TCCD)
Number of subjects: 30
Study 2060540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg t.i.d. for 4 days
Number of subjects: 0
Study 2060540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg t.i.d. for 4 days
Number of subjects: 0
Study 2060540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6344551 — intervention group
Group type: EXPERIMENTAL
Intervention: Urabe Am 9-Schwarz
Number of subjects: 193
Study 6344551 — intervention group
Group type: COMPARATOR
Intervention: Jeryl Lynn-Moraten
Number of subjects: 193
Study 31028610 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epirubicin 150 mg/m2 and cyclophosphamide 1500 mg/m2 with filgrastim support every 3 weeks for 3 cycles (HDEC)
Number of subjects: 235
Study 31028610 — intervention group
Group type: COMPARATOR
Intervention: Standard dose epirubicin 75 mg/m2 and cyclophosphamide 750 mg/m2 every 3 weeks for 6 cycles (SDEC)
Number of subjects: 235
Study 31028610 — intervention group
Group type: EXPERIMENTAL
Intervention: HDEC
Number of subjects: 235
Study 31028610 — intervention group
Group type: COMPARATOR
Intervention: SDEC
Number of subjects: 235
Study 29089403 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR intervention for childhood obesity
Number of subjects: 2000000
Study 26075488 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH (0.15 mg/kg) with ethanol (0.6 g/kg)
Number of subjects: 24
Study 26075488 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐MPH (0.3 mg/kg) with ethanol (0.6 g/kg)
Number of subjects: 24
Study 26075488 — intervention group
Group type: COMPARATOR
Intervention: d‐MPH (0.15 mg/kg)
Number of subjects: 24
Study 23876323 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine administration
Number of subjects: 24
Study 23876323 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 24
Study 21481230 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training programme with injury prevention counselling
Number of subjects: 968
Study 21481230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 968
Study 19383110 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Control Test (ACT) score
Number of subjects: 383
Study 19383110 — intervention group
Group type: COMPARATOR
Intervention: Spirometry, PEFR, FeNO, BHR
Number of subjects: 383
Study 16772451 — intervention group
Group type: COMPARATOR
Intervention: EPO [2100 U EPO/(kg.wk)]
Number of subjects: 3
Study 16772451 — intervention group
Group type: COMPARATOR
Intervention: IV Fe+EPO [2 mg IV sucrose Fe/(kg.d) plus 2100 U EPO/(kg.wk)]
Number of subjects: 3
Study 16772451 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 15588324 — intervention group
Group type: EXPERIMENTAL
Intervention: Information programme and website
Number of subjects: 660
Study 15588324 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis
Number of subjects: 660
Study 15588324 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 660
Study 12439369 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0
Study 7957481 — intervention group
Group type: EXPERIMENTAL
Intervention: Active approach (aggressive rehabilitation program at CPRC, 4-week program of daily physical therapy, occupational therapy, behavioral modification, and counseling)
Number of subjects: 0
Study 7957481 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive approach (functional electric stimulation - FES)
Number of subjects: 0
Study 2820672 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat fiber
Number of subjects: 30
Study 2820672 — intervention group
Group type: COMPARATOR
Intervention: Laxative regime (sterculia, magnesium sulfate, mineral oil)
Number of subjects: 30
Study 29728201 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding (weight gain) for 8 weeks (n=16)
Number of subjects: 26
Study 29728201 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance (control) for 8 weeks (n=10)
Number of subjects: 26
Study 28420352 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention (daily weight measurement using digital scale)
Number of subjects: 826
Study 26200182 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg preoperatively followed by 200 mg every 8 h for 2 days)
Number of subjects: 197
Study 26200182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 26200182 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 197
Study 24119686 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine cardiac magnetic resonance (CMR)
Number of subjects: 0
Study 24119686 — intervention group
Group type: COMPARATOR
Intervention: Selective cardiac magnetic resonance (CMR)
Number of subjects: 0
Study 21309443 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with early vascular dementia (VD)
Number of subjects: 0
Study 21309443 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly controls
Number of subjects: 0
Study 21309443 — intervention group
Group type: COMPARATOR
Intervention: Healthy young controls
Number of subjects: 0
Study 18503806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hold and relax stretching technique of the pectoralis major
Number of subjects: 14
Study 18503806 — intervention group
Group type: COMPARATOR
Intervention: Sham technique
Number of subjects: 14
Study 17196055 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (14.7 mg/day)
Number of subjects: 329
Study 17196055 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (3.9 mg/day)
Number of subjects: 329
Study 17196055 — intervention group
Group type: COMPARATOR
Intervention: Both olanzapine and risperidone
Number of subjects: 329
Study 14514637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 87
Study 14514637 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 10893357 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation (20 parts per million for 30 min at 12‐h intervals until extubation)
Number of subjects: 7
Study 9042260 — intervention group
Group type: EXPERIMENTAL
Intervention: ML-1 standardized mistletoe extract, 1 ng ML-1/kg BW, twice a week for 3 months, starting on day 1 post surgery
Number of subjects: 35
Study 9042260 — intervention group
Group type: COMPARATOR
Intervention: Control group without additional complementary treatment
Number of subjects: 35
Study 9042260 — intervention group
Group type: EXPERIMENTAL
Intervention: ML-1 standardized mistletoe extract
Number of subjects: 35
Study 1580775 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressings
Number of subjects: 39
Study 1580775 — intervention group
Group type: COMPARATOR
Intervention: Saline-gauze dressings
Number of subjects: 39
Study 2578724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (120 mg daily)
Number of subjects: 60
Study 2578724 — intervention group
Group type: COMPARATOR
Intervention: Control (dextran therapy alone)
Number of subjects: 60
Study 30788835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus doxorubicin (Group A)
Number of subjects: 41
Study 30788835 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (Group B)
Number of subjects: 41
Study 29922605 — intervention group
Group type: EXPERIMENTAL
Intervention: SRM‐IV vestibular function diagnosis and treatment system
Number of subjects: 120
Study 29922605 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional manual repositioning procedure
Number of subjects: 120
Study 29922605 — intervention group
Group type: COMPARATOR
Intervention: Combination of treatment drugs (alprostadil and safflower injection) with acclimatization training
Number of subjects: 120
Study 27487437 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong Yi Jinjing (QYJJ)
Number of subjects: 130
Study 24725034 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 324
Study 24725034 — intervention group
Group type: COMPARATOR
Intervention: Advanced Moist Wound Therapy (AMWT)
Number of subjects: 324
Study 22170727 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d
Number of subjects: 67
Study 22170727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 21200420 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 90
Study 21200420 — intervention group
Group type: COMPARATOR
Intervention: Sb(v)
Number of subjects: 90
Study 17396118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) ferric gluconate for eight consecutive hemodialysis sessions spanning 6 weeks with epoetin increased by 25%
Number of subjects: 134
Study 17396118 — intervention group
Group type: COMPARATOR
Intervention: No added iron with epoetin increased by 25%
Number of subjects: 134
Study 15567810 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 2 mg
Number of subjects: 40
Study 15567810 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 5 mg
Number of subjects: 40
Study 15567810 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 10 mg
Number of subjects: 40
Study 15567810 — intervention group
Group type: COMPARATOR
Intervention: control (normal saline)
Number of subjects: 40
Study 12079935 — intervention group
Group type: COMPARATOR
Intervention: 100 IU x kg(‐1) of heparin (group A)
Number of subjects: 60
Study 12079935 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU x kg(‐1) of heparin (group B)
Number of subjects: 60
Study 12079935 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 60
Study 12079935 — intervention group
Group type: COMPARATOR
Intervention: 4F cannula
Number of subjects: 60
Study 12079935 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of heparin
Number of subjects: 60
Study 10539232 — intervention group
Group type: EXPERIMENTAL
Intervention: Role model story newsletters mailed to parents (experimental group)
Number of subjects: 77
Study 10539232 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no newsletters)
Number of subjects: 77
Study 7726462 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear
Number of subjects: 94
Study 7726462 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional appliance
Number of subjects: 94
Study 7726462 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study 2252526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (0.4 g/kg/BW) for 1 week and once per week for 6 months
Number of subjects: 16
Study 2252526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins
Number of subjects: 16
Study 2252526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 7351109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline with memory-aid stickers
Number of subjects: 179
Study 7351109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline without memory-aid stickers
Number of subjects: 179
Study 7351109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (both groups)
Number of subjects: 179
Study 29340869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (10 Hz, n = 15)
Number of subjects: 29
Study 29340869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (10 Hz)
Number of subjects: 29
Study 29340869 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (n = 14)
Number of subjects: 29
Study 29340869 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (n = 26)
Number of subjects: 29
Study 27121531 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline multivitamin users
Number of subjects: 18530
Study 27121531 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported duration of multivitamin use ≥20 years
Number of subjects: 18530
Study 27121531 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline multivitamin use
Number of subjects: 18530
Study 25786042 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 32
Study 25786042 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 32
Study 23024102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate (100 mg/kg)
Number of subjects: 60
Study 23024102 — intervention group
Group type: COMPARATOR
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 60
Study 20630304 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFile Series 29 to size #6 (#36/.06) at working length (WL)
Number of subjects: 124
Study 20630304 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoSequence to #35/.06
Number of subjects: 124
Study 20630304 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFile Series 29 followed by LightSpeed in a hybrid technique to a final size #50
Number of subjects: 124
Study 20630304 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper and additional enlargement with LightSpeed to #50 in a hybrid technique
Number of subjects: 124
Study 18374046 — intervention group
Group type: EXPERIMENTAL
Intervention: Beger procedure
Number of subjects: 65
Study 18374046 — intervention group
Group type: COMPARATOR
Intervention: Berne modification
Number of subjects: 65
Study 16771816 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 5 mg plus RDC
Number of subjects: 261
Study 16771816 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 2.5 mg plus FDC
Number of subjects: 261
Study 16771816 — intervention group
Group type: COMPARATOR
Intervention: MMF plus FDC
Number of subjects: 261
Study 11580823 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) biofeedback (BFB)
Number of subjects: 20
Study 11580823 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical neuromuscular stimulation (TENS)
Number of subjects: 20
Study 11580823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BFB and TENS)
Number of subjects: 20
Study 9847546 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory presentation
Number of subjects: 0
Study 9847546 — intervention group
Group type: COMPARATOR
Intervention: Articulatory suppression
Number of subjects: 0
Study 7994791 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) 50 mg/50 ml saline
Number of subjects: 96
Study 7994791 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (ADM) 50 mg/40 ml saline plus verapamil (VR) 25 mg/10 ml saline
Number of subjects: 96
Study 2464184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast media (iopromide, iopamidol, iohexol)
Number of subjects: 94
Study 2464184 — intervention group
Group type: COMPARATOR
Intervention: Blood-isotonic saline solution
Number of subjects: 94
Study 2464184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast media followed by saline solution
Number of subjects: 94
Study 7816385 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous enhancement method of preparation
Number of subjects: 38
Study 378005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cephalothin
Number of subjects: 34
Study 378005 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefamandole
Number of subjects: 34
Study 378005 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infection rate
Number of subjects: 34
Study 378005 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of anaerobic bacteremia
Number of subjects: 34
Study 30199586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri tu 14
Number of subjects: 32
Study 28285427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative CO2 pressure of 15 mmHg
Number of subjects: 550
Study 28285427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative CO2 pressure of 12 mmHg
Number of subjects: 550
Study 28285427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative CO2 pressure of 10 or 8 mmHg
Number of subjects: 550
Study 27707686 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR+WEB (n=60)
Number of subjects: 109
Study 27707686 — intervention group
Group type: COMPARATOR
Intervention: MMR (n=49)
Number of subjects: 109
Study 27707686 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR+WEB and MMR
Number of subjects: 109
Study 27707686 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR+WEB
Number of subjects: 109
Study 24449031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 50
Study 24449031 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 50
Study 24449031 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 22674529 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (docetaxel 60 mg/m(2) and carboplatin AUC = 5 for 2 cycles) plus concurrent radiation therapy (40 Gy) followed by surgery (CRS arm)
Number of subjects: 60
Study 22674529 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy followed by surgery (CS arm)
Number of subjects: 60
Study 22674529 — intervention group
Group type: EXPERIMENTAL
Intervention: With downstaging
Number of subjects: 60
Study 22674529 — intervention group
Group type: EXPERIMENTAL
Intervention: Without downstaging
Number of subjects: 60
Study 19948631 — intervention group
Group type: EXPERIMENTAL
Intervention: Apgar scores at 10 minutes
Number of subjects: 188
Study 19948631 — intervention group
Group type: EXPERIMENTAL
Intervention: Apgar scores of 0 at 10 minutes
Number of subjects: 188
Study 19948631 — intervention group
Group type: EXPERIMENTAL
Intervention: Apgar scores of 1 at 10 minutes
Number of subjects: 188
Study 19948631 — intervention group
Group type: EXPERIMENTAL
Intervention: Apgar scores of 2 at 10 minutes
Number of subjects: 188